Intro

The chapter features a conversation with the CEO of Avidity Biosciences, delving into their innovative approach to RNA medicines targeting muscle diseases. It highlights the company's clinical trial successes and the potential impact of their technology on patient outcomes in conditions like myotonic dystrophy and Duchenne muscular dystrophy.